Quick Answer
Avalo Therapeutics, Inc. reported Total Revenue of $59.0 thousand for fiscal year 2025.
Avalo Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $59.0K -86.6% |
$441.0K -77.1% |
$1.92M -89.3% |
$18.05M +234.4% |
$5.40M -19.4% |
$6.70M -0.8% |
| Revenue (ASC 606) | $59.0K -86.6% |
$441.0K -77.1% |
$1.92M -89.3% |
$18.05M +234.4% |
$5.40M -19.4% |
$6.70M -0.8% |
| Net Income | -$78.26M -122.8% |
-$35.13M -11.4% |
-$31.54M +24.3% |
-$41.66M +50.6% |
-$84.38M -32.9% |
-$63.50M -295.1% |
| Diluted EPS | -$5.84 +72.1% |
-$20.91 +81.6% |
-$113.58 +89.3% |
-$1063.00 | — | — |
| Total Assets | $116.46M -22.7% |
$150.73M +618.0% |
$20.99M -37.1% |
$33.37M -58.4% |
$80.21M +83.3% |
$43.76M +21.2% |
| Cash and Equivalents | $15.86M -88.2% |
$134.55M +1714.5% |
$7.42M -43.7% |
$13.17M -75.9% |
$54.59M +188.5% |
$18.92M +424.2% |
| Long-Term Debt | — | — | — | — | — | — |
| Stockholders Equity | $83.05M -37.6% |
$133.03M +1721.4% |
$7.30M +166.9% |
-$10.91M -147.3% |
$23.08M -6.0% |
$24.56M +17.0% |
| R&D Expense | — | — | — | — | — | — |
| Operating Income | -$72.92M -6.4% |
-$68.51M -150.5% |
-$27.35M +26.9% |
-$37.44M +54.4% |
-$82.13M -12.8% |
-$72.84M -351.4% |
| Shares Outstanding | 18.51M +76.8% |
10.47M +1206.1% |
801,746 +1940.4% |
39,294 -99.6% |
9.40M -87.5% |
75.00M +69.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $0.00 | -100.0% | -100.0% |
| Revenue (ASC 606) | September 30, 2025 | $0.00 | -100.0% | -100.0% |
| Net Income | September 30, 2025 | -$30.62M | -232.9% | -47.5% |
| Diluted EPS | September 30, 2025 | -$2.19 | +22.6% | -14.1% |
| Total Assets | September 30, 2025 | $125.10M | +27.1% | -1.2% |
| Cash and Equivalents | September 30, 2025 | $26.96M | -67.1% | -36.2% |
| Long-Term Debt | September 30, 2019 | $14.25M | -0.7% | -0.2% |
| Stockholders Equity | September 30, 2025 | $91.55M | +334.4% | -12.5% |
| R&D Expense | March 31, 2019 | $3.40M | +106.2% | +214.1% |
| Operating Income | September 30, 2025 | -$19.20M | -49.3% | +0.6% |
| Shares Outstanding | September 30, 2025 | 17.83M | +84.1% | +64.5% |
- Avalo Therapeutics, Inc. reported Total Revenue of $59.0 thousand for fiscal year 2025.
- Avalo Therapeutics, Inc. showed a decrease of -86.6% in Total Revenue compared to the prior fiscal year.
- Avalo Therapeutics, Inc. reported Revenue (ASC 606) of $59.0 thousand for fiscal year 2025.
- Avalo Therapeutics, Inc. showed a decrease of -86.6% in Revenue (ASC 606) compared to the prior fiscal year.
- Avalo Therapeutics, Inc. reported Net Income of -$78.26 million for fiscal year 2025.
- Avalo Therapeutics, Inc. showed a decrease of -122.8% in Net Income compared to the prior fiscal year.
- Avalo Therapeutics, Inc. reported Diluted EPS of $5.84 per share (loss) for fiscal year 2025.
- Avalo Therapeutics, Inc. showed an increase of +72.1% in Diluted EPS compared to the prior fiscal year.
- Avalo Therapeutics, Inc. reported Total Assets of $116.46 million for fiscal year 2025.
- Avalo Therapeutics, Inc. showed a decrease of -22.7% in Total Assets compared to the prior fiscal year.
- Avalo Therapeutics, Inc. reported Cash and Equivalents of $15.86 million for fiscal year 2025.
- Avalo Therapeutics, Inc. showed a decrease of -88.2% in Cash and Equivalents compared to the prior fiscal year.
- Avalo Therapeutics, Inc. reported Long-Term Debt of $14.33 million for fiscal year 2018.
- Avalo Therapeutics, Inc. reported Stockholders Equity of $83.05 million for fiscal year 2025.
- Avalo Therapeutics, Inc. showed a decrease of -37.6% in Stockholders Equity compared to the prior fiscal year.
- Avalo Therapeutics, Inc. reported R&D Expense of $5.79 million for fiscal year 2018.
- Avalo Therapeutics, Inc. showed an increase of +32.3% in R&D Expense compared to the prior fiscal year.
- Avalo Therapeutics, Inc. reported Operating Income of -$72.92 million for fiscal year 2025.
- Avalo Therapeutics, Inc. showed a decrease of -6.4% in Operating Income compared to the prior fiscal year.
- Avalo Therapeutics, Inc. reported Shares Outstanding of 18.51 million shares for fiscal year 2025.
- Avalo Therapeutics, Inc. showed an increase of +76.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: